跳至主要内容
临床试验/JPRN-jRCTs041210033
JPRN-jRCTs041210033已完成3 期

Effectiveness of sofpironium bromaide gel for clozapine-induced hypersalivation in patients with treatment-ressistant schizophrenia:A double-blind comparative study (Effectiveness of ECCLOCKgel for clozapine-induced hypersalivation)

Amano Yuhei0 个研究点目标入组 16 人开始时间: 2021年6月17日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
16

研究概览

简要总结

We suggest that sofpironium bromide gel is effective in treating clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Patients diagnosed as schizophrenia according to DSM-5 diagnostic criteria
  • 2. Patients who have been continuously taking clozapine for at least 8 weeks prior to enrollment and have moderate or excessive drooling (5 points or more on the Drooling Severity and Frequency Scale)
  • 3. Inpatients and outpatients
  • 4. Patients who can provide written consent for participation in this study from themselves or their guardians

排除标准

  • 1.Patients with obvious deterioration of psychiatric symptoms within the past 4 weeks
  • 2.Patients whose general condition has deteriorated within the past 4 weeks, and whose participation in the study is judged to be inappropriate.
  • 3.Patients with closed-angle glaucoma, dysuria due to prostatic hypertrophy, and patients with a history of hypersensitivity to the ingredients of Sofpironium bromide gel
  • 4.Patients taking oral anticholinergic medication
  • 5.Patients who are judged by the physician to be inappropriate for the study.

研究者

发起方
Amano Yuhei

相似试验